Trichostatin A and oncolytic HSV combination therapy shows enhanced antitumoral and antiangiogenic effects

Molecular Therapy

Volumn 16, Issue 6, 2008, Pages 1041-1047

  Liu, Ta Chiang ^a,b   Castelo Branco, Pedro ^a   Rabkin, Samuel D ^a   Martuza, Robert L ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b Jennerex Biotherapeutics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; G 47 DELTA; ONCOLYTIC HERPES VIRUS; TRICHOSTATIN A; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CYTOGENETICS; CYTOTOXICITY; DRUG MECHANISM; DRUG POTENTIATION; ENDOTHELIUM CELL; FEMALE; GENE MUTATION; GLIOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MONOTHERAPY; MOUSE; NONHUMAN; PROSTATE EPITHELIUM; TUMOR VASCULARIZATION; VIRUS INFECTIVITY; VIRUS REPLICATION;

ANIMALIA; SIMPLEXVIRUS;

EID: 44349124084     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2008.58     Document Type: Article

References (50)

1. Parato, KA, Senger, D, Forsyth, PA and Bell, JC (2005). Recent progress in the battle between oncolytic viruses and tumours. Nat Rev Cancer 5: 965-976.
2. Liu, TC, Galanis, E and Kirn, D (2007). Clinical trial results with oncolytic virotherapy: A century of promise, a decade of progress. Nat Clin Pract Oncol 4: 101-117.
3. Liu, TC and Kirn, D (2007). Systemic efficacy with oncolytic virus therapeutics: Clinical proof-of-concept and future directions. Cancer Res 67: 429-432.
4. Thorne, SH, Negrin, RS and Contag, CH (2006). Synergistic antitumor effects of immune cell-viral biotherapy. Science 311: 1780-1784.
5. Marks, P, Rifkind, RA, Richon, VM, Breslow, R, Miller, T and Kelly, WK (2001). Histone deacetylases and cancer: Causes and therapies. Nat Rev Cancer 1: 194-202.
6. Marks, PA, Richon, VM and Rifkind, RA (2000). Histone deacetylase inhibitors: Inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst 92: 1210-1216.
7. He, LZ, Tolentino, T, Grayson, P, Zhong, S, Warrell, RP Jr., Rifkind, RA et al. (2001). Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia. J Clin Invest 108: 1321-1330.
8. Johnstone, RW (2002). Histone-deacetylase inhibitors: Novel drugs for the treatment of cancer. Nat Rev Drug Discov 1: 287-299.
9. Kim, MS, Kwon, HJ, Lee, YM, Baek, JH, Jang, JE, Lee, SW et al. (2001). Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat Med 7: 437-443.
10. Kelly, WK and Marks, PA (2005). Drug insight: Histone deacetylase inhibitors development of the new targeted anticancer agent suberoylanilide hydroxamic acid. Nat Clin Pract Oncol 2: 150-157.
11. Minucci, S and Pelicci, PG (2006). Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 6: 38-51.
12. Dowdy, SC, Jiang, S, Zhou, XC, Hou, X, Jin, F, Podratz, KC et al. (2006). Histone deacetylase inhibitors and paclitaxel cause synergistic effects on apoptosis and microtubule stabilization in papillary serous endometrial cancer cells. Mol Cancer Ther 5: 2767-2776.
13. Qi, H and Ratnam, M (2006). Synergistic induction of folate receptor beta by all-trans retinoic acid and histone deacetylase inhibitors in acute myelogenous leukemia cells: Mechanism and utility in enhancing selective growth inhibition by antifolates. Cancer Res 66: 5875-5882.
14. Piacentini, P, Donadelli, M, Costanzo, C, Moore, PS, Palmieri, M and Scarpa, A (2006). Trichostatin A enhances the response of chemotherapeutic agents in inhibiting pancreatic cancer cell proliferation. Virchows Arch 448: 797-804.
15. Archer, SY, Meng, S, Shei, A and Hodin, RA (1998). p21(WAF1) is required for butyrate-mediated growth inhibition of human colon cancer cells. Proc Natl Acad Sci USA 95: 6791-6796.
16. Nakata, S, Yoshida, T, Horinaka, M, Shiraishi, T, Wakada, M and Sakai, T (2004). Histone deacetylase inhibitors upregulate death receptor 5/ TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells. Oncogene 23: 6261-6271.
17. Rahmani, M, Reese, E, Dai, Y, Bauer, C, Payne, SG, Dent, P et al. (2005). Coadministration of histone deacetylase inhibitors and perifosine synergistically induces apoptosis in human leukemia cells through Akt and ERK1/2 inactivation and the generation of ceramide and reactive oxygen species. Cancer Res 65: 2422-2432.
18. Kitazono, M, Goldsmith, ME, Aikou, T, Bates, S and Fojo, T (2001). Enhanced adenovirus transgene expression in malignant cells treated with the histone deacetylase inhibitor FR901228. Cancer Res 61: 6328-6330.
19. Okada, T, Uchibori, R, Iwata-Okada, M, Takahashi, M, Nomoto, T, Nonaka-Sarukawa, M et al. (2006). A histone deacetylase inhibitor enhances recombinant adeno-associated virus-mediated gene expression in tumor cells. Mol Ther 13: 738-746.
20. Bieler, A, Mantwill, K, Dravits, T, Bernshausen, A, Glockzin, G, Kohler-Vargas, N et al. (2006). Novel three-pronged strategy to enhance cancer cell killing in glioblastoma cell lines: Histone deacetylase inhibitor, chemotherapy, and oncolytic adenovirus dl520. Hum Gene Ther 17: 55-70.
21. Vigushin, DM, Ali, S, Pace, PE, Mirsaidi, N, Ito, K, Adcock, I et al. (2001). Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo. Clin Cancer Res 7: 971-976.
22. Deroanne, CF, Bonjean, K, Servotte, S, Devy, L, Colige, A, Clausse, N et al. (2002). Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling. Oncogene 21: 427-436.
23. Qian, DZ, Kato, Y, Shabbeer, S, Wei, Y, Verheul, HM, Salumbides, B et al. (2006). Targeting tumor angiogenesis with histone deacetylase inhibitors: The hydroxamic acid derivative LBH589. Clin Cancer Res 12: 634-642.
24. Liu, TC, Zhang, T, Fukuhara, H, Kuroda, T, Todo, T, Canron, X et al. (2006). Dominant-negative fibroblast growth factor receptor expression enhances antitumoral potency of oncolytic herpes simplex virus in neural tumors. Clin Cancer Res 12: 6791-6799.
25. Chen, BX and Erlanger, BF (2006). Cell cycle inhibition by an anti-cyclin D1 antibody chemically modified for intracellular delivery. Cancer Lett 244: 71-75.
26. Aghi, M, Rabkin, S and Martuza, RL (2006). Effect of chemotherapy-induced DNA repair on oncolytic herpes simplex viral replication. J Natl Cancer Inst 98: 38-50.
27. Knudsen, KE, Diehl, JA, Haiman, CA and Knudsen, ES (2006). Cyclin D1: polymorphism, aberrant splicing and cancer risk. Oncogene 25 1620-1628.
28. Alao, JP (2007). The regulation of cyclin D1 degradation: Roles in cancer development and the potential for therapeutic invention. Mol Cancer 6: 24.
29. Hu, J and Colburn, NH (2005). Histone deacetylase inhibition down-regulates cyclin D1 transcription by inhibiting nuclear factor-B/ p65 DNA binding. Mol Cancer Res 3: 100-109.
30. Song, B, Yeh, KC, Liu, J and Knipe, DM (2001). Herpes simplex virus gene products required for viral inhibition of expression of G1-phase functions. Virology 290: 320-328.
31. Ben-Israel, H and Kleinberger, T (2002). Adenovirus and cell cycle control. Front Biosci 7: d1369-d1395.
32. Yasui, M, Yamamoto, H, Ngan, CY, Damdinsuren, B, Sugita, Y, Fukunaga, H et al. (2006). Antisense to cyclin D1 inhibits vascular endothelial growth factor-stimulated growth of vascular endothelial cells: Implication of tumor vascularization. Clin Cancer Res 12 4720-4729.
33. Cinatl, J Jr., Michaelis, M, Driever, PH, Cinatl, J, Hrabeta, J, Suhan, T et al. (2004). Multimutated herpes simplex virus g207 is a potent inhibitor of angiogenesis. Neoplasia 6: 725-735.
34. Benencia, F, Courreges, MC, Conejo-Garcia, JR, Buckanovich, RJ, Zhang, L, Carroll, RH et al. (2005). Oncolytic HSV exerts direct antiangiogenic activity in ovarian carcinoma. Hum Gene Ther 16 765-778.
35. Aghi, M, Rabkin, SD and Martuza, RL (2007). Angiogenic response caused by oncolytic herpes simplex virus-induced reduced thrombospondin expression can be prevented by specific viral mutations or by administering a thrombospondin-derived peptide. Cancer Res 67 440-444.
36. Breitbach, CJ, Paterson, JM, Lemay, CG, Falls, TJ, McGuire, A, Parato, KA et al. (2007). Targeted inflammation during oncolytic virus therapy severely compromises tumor blood flow. Mol Ther 15: 1686-1693.
37. Maecker, HL, Yun, Z, Maecker, HT and Giaccia, AJ (2002). Epigenetic changes in tumor Fas levels determine immune escape and response to therapy. Cancer Cell 2: 139-148.
38. Moreira, JM, Scheipers, P and Sorensen, P (2003). The histone deacetylase inhibitor Trichostatin A modulates CD4+ T cell responses. BMC Cancer 3: 30.
39. Magner, WJ and Tomasi, TB (2005). Apoptotic and necrotic cells induced by different agents vary in their expression of MHC and costimulatory genes. Mol Immunol 42: 1033-1042.
40. Poon, AP, Liang, Y and Roizman, B (2003). Herpes simplex virus 1 gene expression is accelerated by inhibitors of histone deacetylases in rabbit skin cells infected with a mutant carrying a cDNA copy of the infected-cell protein no. 0. J Virol 77: 12671-12678.
41. Miller, CS, Danaher, RJ and Jacob, RJ (2006). ICP0 is not required for efficient stress-induced reactivation of herpes simplex virus type 1 from cultured quiescently infected neuronal cells. J Virol 80 3360-3368.
42. Chang, HM, Paulson, M, Holko, M, Rice, CM, Williams, BR, Marie, I et al. (2004). Induction of interferon-stimulated gene expression and antiviral responses require protein deacetylase activity. Proc Natl Acad Sci USA 101: 9578-9583.
43. Adusumilli, PS, Chan, MK, Chun, YS, Hezel, M, Chou, TC, Rusch, VW et al. (2006). Cisplatin-induced GADD34 upregulation potentiates oncolytic viral therapy in the treatment of malignant pleural mesothelioma. Cancer Biol Ther 5: 48-53.
44. Raki, M, Kanerva, A, Ristimaki, A, Desmond, RA, Chen, DT, Ranki, T et al. (2005). Combination of gemcitabine and Ad5/3-Delta24, a tropism modified conditionally replicating adenovirus, for the treatment of ovarian cancer. Gene Ther 12: 1198-1205.
45. Liu, TC, Zhang, T, Fukuhara, H, Kuroda, T, Todo, T, Martuza, RL et al. (2006). Oncolytic HSV armed with platelet factor 4, an antiangiogenic agent, shows enhanced efficacy. Mol Ther 14: 789-797.
46. Wong, RJ, Chan, MK, Yu, Z, Ghossein, RA, Ngai, I, Adusumilli, PS et al. (2004). Angiogenesis inhibition by an oncolytic herpes virus expressing interleukin 12. Clin Cancer Res 10: 4509-4516.
47. Yoo, JY, Kim, JH, Kwon, YG, Kim, EC, Kim, NK, Choi, HJ et al. (2007). VEGF-specific short hairpin RNA-expressing oncolytic adenovirus elicits potent inhibition of angiogenesis and tumor growth. Mol Ther 15: 295-302.
48. Kurozumi, K, Hardcastle, J, Thakur, R, Yang, M, Christoforidis, G, Fulci, G et al. (2007). Effect of tumor microenvironment modulation on the efficacy of oncolytic virus therapy. J Natl Cancer Inst 99: 1768-1781.
49. Todo, T, Martuza, RL, Rabkin, SD and Johnson, PA (2001). Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing. Proc Natl Acad Sci USA 98: 6396-6401.
50. DeLuca, NA, McCarthy, AM and Schaffer, PA (1985). Isolation and characterization of deletion mutants of herpes simplex virus type 1 in the gene encoding immediate-early regulatory protein ICP4. J Virol 56: 558-570.